High Court Pauses Change to Mail Delivery of Abortion Pill

On May 11, 2026, Justice Samuel A. Alito Jr. extended an administrative stay that pauses a federal appeals court order affecting how mifepristone is dispensed. The brief order followed emergency filings by Danco Laboratories and GenBioPro, which asked the Supreme Court to preserve mail and telehealth access while the dispute is resolved. The action keeps current FDA dispensing policies in place for a short period while the justices consider the requests.

The appeals court in New Orleans, the 5th U.S. Circuit Court of Appeals, had directed that mifepristone be picked up in person, a change that would have ended routine teleprescribing and mail delivery. Louisiana's lawsuit argued that the FDA's relaxation of in-person rules had undermined state abortion restrictions, and the appellate judges agreed for now. Medical providers had relied on the FDA's prior guidance and on telehealth systems that had been used widely since the agency eased dispensing rules.

Clinics, pharmacies, and patients have reported anxiety and disruption as court orders have shifted rapidly, and drugmakers warned of regulatory chaos if the appeals decision took immediate effect. Legal briefing deadlines and procedural steps are now shaping the timetable; the temporary pause has been set to last until at least Thursday, May 14, 2026, while the court considers further filings. If the Supreme Court declines to extend the pause, the appeals court's changes could be enforced, and providers would need to adjust quickly.

Observers say the case could have broader implications for how courts review agency decisions and for access to time-sensitive medical care. For the moment, mail and telehealth remain options for patients seeking mifepristone as the high court weighs its next move.